Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals
Dluzynski et al., Scientific Reports, doi:10.1038/s41598-025-02240-3
https://c19early.org/dluzynski.html